Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Explore this paper's citation graph
Summary
In patients with resectable adenocarcinoma of the lower esophagus, GEJ, or stomach, perioperative chemotherapy using fluorouracil plus cisplatin significantly increased the curative resection rate, disease-free survival, and OS.
- Type
- article
- Published
- 2011-05-01
- Cited by
- 1,834
- References
- 31
- Access
- Open access
- OpenAlex
- https://openalex.org/W2146834306
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:42348223
Keywords
Medicine, Perioperative, Adenocarcinoma, Surgery, Regimen
References
- Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: Phase II study with methotrexate and 5‐fluorouracil
- Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.
- Prognostic factors for local control after breast conservation: does margin status still matter?
- Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction.
- Prognostic relevance of systematic lymph node dissection in gastric carcinoma
- Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
- A partially grouped logrank test.
- Novel targets in gastric and esophageal cancer.
- Neoadjuvant Treatment for Resectable Cancer of the Esophagus and the Gastroesophageal Junction: A Meta-Analysis of Randomized Clinical Trials
- Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum.
- Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
- Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
- Individual Patient Data-based Meta-analysis Assessing the Effect of Preoperative Chemo-radiotherapy in Resectable Oesophageal Carcinoma
- Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
- Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
- Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
- Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
- Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
- Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
- Management of gastroesophageal tumors.
Cited by
- Magen- und Adenokarzinome des ösophagogastralen Übergangs
- Comparative effectiveness in esophagogastric cancer.
- Capecitabine in gastric cancer
- Cancers de l’estomac
- Adjuvant chemotherapy: an option for Asian patients only?
- Operable gastro-oesophageal junctional adenocarcinoma: Where to next?
- Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction: A Meta-Analysis
- A Phase II Trial of Induction Epirubicin, Oxaliplatin, and Fluorouracil, Followed by Surgery and Postoperative Concurrent Cisplatin and Fluorouracil Chemoradiotherapy in Patients with Locoregionally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction
- The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction.
- Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma
- Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer
- Preoperative Chemoradiation Therapy Versus Chemotherapy in Patients Undergoing Modified En Bloc Esophagectomy for Locally Advanced Esophageal Adenocarcinoma: Is Radiotherapy Beneficial?
- Current adjuvant treatment modalities for gastric cancer: From history to the future.
- Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction.
- Utilization of Surgical Treatment for Local and Locoregional Esophageal Cancer: Analysis of the National Cancer Data Base
- The influence of neoadjuvant chemotherapy on gastric cancer patients’ postoperative infectious complications: What is the negative role played by the intestinal barrier dysfunction?
- Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?
- Multimodal treatment of gastric cancer.
- Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis
- Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
Related papers
- The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin.
- The Relationship between Expression of 1-Cys Peroxiredoxin and Resistance to Cisplatin in Epithelial Ovarian Cancer Cell Lines
- Antitumor effect of radioactive cisplatin (191Pt) on nude mice.
- Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.
- Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
- Transarterial Chemoembolization Using Cisplatin Powder in a Rabbit Model of Liver Cancer
- New combination chemotherapy of cisplatin with an electron-donating compound for treatment of multiple cancers
- Metoclopramide as a modulator of cisplatin: effects on pharmacokinetics and cisplatin–DNA adducts in tumor and normal tissue
- Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines.